Zila's OraTest Rinse Needs Additional Study, FDA Advisory Committee Says
This article was originally published in The Gray Sheet
Executive Summary
Zila should conduct another trial of its OraTest oral cancer diagnostic, FDA's Oncology Drugs Advisory Committee determined Jan. 13.